EP cancer control move promising for medtech
This article was originally published in Clinica
The EU market for diagnostic tests and imaging procedures for diagnosing cancer, as well as for radiotherapy equipment, would "explode" if the European Parliament was able to push through all of its proposals for tackling cancer that are contained in a Resolution adopted by MEPs during a debate on April 10. One third of cancers in the EU could be cured if detected early and treated appropriately. Another third are preventable, the Parliament stated in its motion for the resolution that was adopted.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.